{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T14:14:49Z","timestamp":1786976089209,"version":"build-2736575974"},"update-to":[{"DOI":"10.1002\/14651858.cd006617.pub2","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2008,7,16]],"date-time":"2008-07-16T00:00:00Z","timestamp":1216166400000}}],"reference-count":148,"publisher":"Wiley","issue":"7","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd006617.pub3","type":"journal-article","created":{"date-parts":[[2008,6,30]],"date-time":"2008-06-30T07:24:52Z","timestamp":1214810692000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Aripiprazole versus typical antipsychotic drugs for schizophrenia"],"prefix":"10.1002","volume":"2014","author":[{"given":"Jayanti","family":"Bhattacharjee","sequence":"first","affiliation":[{"name":"National Institute of Behavioural Sciences; Psychiatry; P-7, C.I.T. Road, Ist Floor, Moulali Kolkata West Bengal India 700050"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hany G","family":"El-Sayeh","sequence":"additional","affiliation":[{"name":"Tees, Esk & Wear Valleys NHS Foundation Trust; Harrogate District Hospital; Briary Wing Lancaster Park Road Harrogate North Yorkshire UK HG2 7SX"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2008,7,16]]},"reference":[{"key":"10.1002\/14651858.CD006617.pub3-BIB0001|cit1","doi-asserted-by":"crossref","first-page":"103s","DOI":"10.1016\/S0924-9338(02)80465-5","article-title":"Controlled study of aripiprazole and haloperidol in schizophrenia","volume":"Suppl 1","author":"Anutosh","year":"2002","journal-title":"European Psychiatry"},{"key":"10.1002\/14651858.CD006617.pub3-BIB0002|cit2","unstructured":"Aquino P CE Adams T Crow I Wood Personal communication Personal Communication 2006"},{"key":"10.1002\/14651858.CD006617.pub3-BIB0003|cit3","first-page":"221","article-title":"A double-blind, placebo-controlled trial of aripiprazole and haloperidol","volume":"1-2","author":"Carson","year":"2001","journal-title":"Schizophrenia Research"},{"key":"10.1002\/14651858.CD006617.pub3-BIB0004|cit4","doi-asserted-by":"crossref","unstructured":"Carson WH Ali M Saha AR Dunbar GC Ingenito G A double-blind, placebo-controlled trial of aripiprazole and haloperidol in patients with schizophrenia or schizoaffective disorder 39th Annual Meeting of the American College of Neuropsychopharmacology; 2000; Dec 10-14; San Juan; Puerto Rico 2000 76237990","DOI":"10.1016\/S0924-977X(00)80358-2"},{"issue":"Suppl 3","key":"10.1002\/14651858.CD006617.pub3-BIB0005|cit5","doi-asserted-by":"crossref","first-page":"S309","DOI":"10.1016\/S0924-977X(00)80358-2","article-title":"Efficacy of aripiprazole in psychotic disorders: comparison with haloperidol and placebo","volume":"10","author":"Carson","year":"2000","journal-title":"Journal of the European College of Neuropsychopharmacology"},{"key":"10.1002\/14651858.CD006617.pub3-BIB0006|cit6","unstructured":"Dubitsky GM Harris R Laughren T Hardeman S Abilify (aripiprazole) tablets, medical review part 1 www.fda.gov\/cder\/foi\/nda\/2002\/21-436_Abilify.htm 2002 1 50"},{"key":"10.1002\/14651858.CD006617.pub3-BIB0007|cit7","unstructured":"Dubitsky GM Harris R Laughren T Hardeman S Abilify (aripiprazole) tablets, medical review part 3 www.fda.gov\/cder\/foi\/nda\/2002\/21-436_Abilify.htm 2002 111 175"},{"key":"10.1002\/14651858.CD006617.pub3-BIB0008|cit8","unstructured":"Dubitsky GM Harris R Laughren T Hardeman S Abilify (aripiprazole) tablets, medical review part 4 www.fda.gov\/cder\/foi\/nda\/2002\/21-436_Abilify.htm 176 232"},{"key":"10.1002\/14651858.CD006617.pub3-BIB0009|cit9","unstructured":"Dubitsky GM Harris R Laughren T Hardeman S Abilify (aripiprazole) tablets; medical review part 2 www.fda.gov\/cder\/foi\/nda\/2002\/21-436_Abilify.htm 2002 50 110"},{"key":"10.1002\/14651858.CD006617.pub3-BIB0010|cit10","unstructured":"European Medicines Agency Abilify H-C-471; European Public Assessment Report; Scientific discussion http:\/\/www.emea.europa.eu\/humandocs\/ 2007"},{"key":"10.1002\/14651858.CD006617.pub3-BIB0011|cit11","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/S0920-9964(00)90383-9","article-title":"Efficacy of aripiprazole in psychotic disorders: comparison with haloperidol and placebo","volume":"1","author":"Kane","year":"2000","journal-title":"Schizophrenia Research"},{"key":"10.1002\/14651858.CD006617.pub3-BIB0012|cit12","doi-asserted-by":"crossref","first-page":"763","DOI":"10.4088\/JCP.v63n0903","article-title":"Efficacy and safety of aripiprazole and haloperidol versus placebo in patients with schizophrenia and schizoaffective disorder","volume":"9","author":"Kane","year":"2002","journal-title":"Journal of Clinical Psychiatry"},{"key":"10.1002\/14651858.CD006617.pub3-BIB0013|cit13","unstructured":"Kane JM Ingenito G Ali M Efficacy of aripiprazole in psychotic disorders: comparison with haloperidol and placebo 153rd Annual Meeting of the American Psychiatric Association; 2000 May 13-18; Chicago, USA 2000"},{"key":"10.1002\/14651858.CD006617.pub3-BIB0014|cit14","unstructured":"Kane JM Ingenito G Ali M Efficacy of aripiprazole in psychotic disorders: comparison with haloperidol and placebo 155th Annual Meeting of the American Psychiatric Association; 2002 May 18-23; Philadelphia, PA, USA 2002"},{"key":"10.1002\/14651858.CD006617.pub3-BIB0015|cit15","first-page":"S124","article-title":"Efficacy of aripiprazole in psychotic disorders: comparison with haloperidol and placebo","volume":"Suppl 1","author":"Kane","year":"2000","journal-title":"International Journal of Neuropsychopharmacology"},{"key":"10.1002\/14651858.CD006617.pub3-BIB0016|cit16","unstructured":"Dubitsky GM Harris R Laughren T Hardeman S Abilify (aripiprazole) tablets, medical review part 1 www.fda.gov\/cder\/foi\/nda\/2002\/21-436_Abilify.htm 2002 1 50"},{"key":"10.1002\/14651858.CD006617.pub3-BIB0017|cit17","unstructured":"Dubitsky GM Harris R Laughren T Hardeman S Abilify (aripiprazole) tablets, medical review part 2 www.fda.gov\/cder\/foi\/nda\/2002\/21-436_Abilify.htm 2002 51 110"},{"key":"10.1002\/14651858.CD006617.pub3-BIB0018|cit18","unstructured":"Dubitsky GM Harris R Laughren T Hardeman S Abilify (aripiprazole) tablets, medical review part 3 www.fda.gov\/cder\/foi\/nda\/2002\/21-436_Abilify.htm 2002 111 175"},{"key":"10.1002\/14651858.CD006617.pub3-BIB0019|cit19","unstructured":"Dubitsky GM Harris R Laughren T Hardeman S Abilify (aripiprazole) tablets; medical review part 4 www.fda.gov\/cder\/foi\/nda\/2002\/21-436_Abilify.htm 2002 176 232"},{"key":"10.1002\/14651858.CD006617.pub3-BIB0020|cit20","unstructured":"European Medicines Agency Abilify H-C-471; European Public Assessment Report; Scientific discussion http:\/\/www.emea.europa.eu\/humandocs\/ 2007"},{"key":"10.1002\/14651858.CD006617.pub3-BIB0021|cit21","first-page":"S157","article-title":"Aripiprazole, a novel antipsychotic: overview of a phase II study result","volume":"Suppl 1","author":"Daniel","year":"2000","journal-title":"International Journal of Neuropsychopharmacology"},{"key":"10.1002\/14651858.CD006617.pub3-BIB0022|cit22","unstructured":"Dubitsky GM Harris R Laughren T Hardeman S Abilify (aripiprazole) tablets ; medical review part 2 www.fda.gov\/cder\/foi\/nda\/2002\/21-436_Abilify.htm 2002 50 110"},{"key":"10.1002\/14651858.CD006617.pub3-BIB0023|cit23","unstructured":"Dubitsky GM Harris R Laughren T Hardeman S Abilify (aripiprazole) tablets, medical review part 1 www.fda.gov\/cder\/foi\/nda\/2002\/21-436_Abilify.htm 2002 1 50"},{"key":"10.1002\/14651858.CD006617.pub3-BIB0024|cit24","unstructured":"Dubitsky GM Harris R Laughren T Hardeman S Abilify (aripiprazole) tablets, medical review part 3 www.fda.gov\/cder\/foi\/nda\/2002\/21-436_Abilify.htm 2002 111 175"},{"key":"10.1002\/14651858.CD006617.pub3-BIB0025|cit25","unstructured":"Dubitsky GM Harris R Laughren T Hardeman S Abilify (aripiprazole) tablets; medical review part 4 www.fda.gov\/cder\/foi\/nda\/2002\/21-436_Abilify.htm 2002 176 232"},{"key":"10.1002\/14651858.CD006617.pub3-BIB0026|cit26","unstructured":"European Medicines Agency Abilify H-C-471; European Public Assessment Report; Scientific discussion http:\/\/www.emea.europa.eu\/humandocs\/ 2007"},{"key":"10.1002\/14651858.CD006617.pub3-BIB0027|cit27","first-page":"295","article-title":"Safety and efficacy profile of aripiprazole, a novel antipsychotic","volume":"1-3","author":"Saha","year":"1999","journal-title":"Schizophrenia Research"},{"key":"10.1002\/14651858.CD006617.pub3-BIB0028|cit28","unstructured":"Daniel DG Stock EG Wilber CH Marcus RN Carson Jr WH Manos G Iwamoto T Intramuscular aripiprazole in acutely agitated psychotic patients 157th Annual Meeting of the American Psychiatric Association; 2004 May 1-6; New York, Usa 2004"},{"issue":"Suppl.3","key":"10.1002\/14651858.CD006617.pub3-BIB0029|cit29","doi-asserted-by":"crossref","first-page":"S261","DOI":"10.1016\/S0924-977X(04)80286-4","article-title":"Intramuscular aripiprazole treatment for acute agitation in patients with psychosis","volume":"14","author":"Gismondi","year":"2004","journal-title":"Journal of the European College of Neuropsychopharmacology"},{"key":"10.1002\/14651858.CD006617.pub3-BIB0030|cit30","unstructured":"Kungel M Daniel D Stock E Wilber R Marcus R Carson W Manos G Iwamoto T Efficacy and safety of intramuscular aripiprazole in acutely agitated patients with psychosis Thematic Conference of the World Psychiatric Association on \"Treatments in Psychiatry: An Update\"; 2004 Nov 10-13; Florence, Italy 2004"},{"key":"10.1002\/14651858.CD006617.pub3-BIB0031|cit31","unstructured":"Modell S Daniel D Stock E Wilber R Marcus R Carson W Manos G Iwamoto T Intramuscular aripiprazole treatment for acute agitation in patients with psychosis XXIVth Collegium Internationale Neuro-Psychopharmacologicum Congress; 2004 June 20-24, Paris, France 2004"},{"issue":"1","key":"10.1002\/14651858.CD006617.pub3-BIB0032|cit32","doi-asserted-by":"crossref","first-page":"111","DOI":"10.4088\/JCP.v68n0115","article-title":"Efficacy and safety of intramuscular aripiprazole in patients with acute agitation: a randomised double-blind,placebo-controlled trial","volume":"68","author":"Tran-Johnson","year":"2007","journal-title":"Journal of Clinical Psychiatry"},{"key":"10.1002\/14651858.CD006617.pub3-BIB0033|cit33","unstructured":"Yocca F Daniel D Stock E Oren D Marcus R Carson W Manos G Iwamoto T Efficacy and safety of intramuscular aripiprazole treatment for acute agitation in patients with psychosis 43rd Annual Meeting of the American College of Neuropsychopharmacology ; 2004 Dec 12-16, San Juan, Puerto Rico 2004"},{"key":"10.1002\/14651858.CD006617.pub3-BIB0034|cit34","unstructured":"Gismondi R Meltzer H Kujawa M Carson W Stringfellow J Iwamoto T Marcus R Stock E Aipiprazole versus perphenazine in treatment-resistant schizophrenia XXIVth Collegium Internationale Neuro-Psychopharmacologicum Congress ; 2004 June 20-24, Paris, France 2004"},{"issue":"1","key":"10.1002\/14651858.CD006617.pub3-BIB0035|cit35","first-page":"155","article-title":"Aripiprazole in Treatment-Resistant Schizophrenia: a 6-Week Double- Blind Comparison Study Versus Perphenazine","volume":"67","author":"Kane","year":"2004","journal-title":"Schizophrenia Research"},{"key":"10.1002\/14651858.CD006617.pub3-BIB0036|cit36","unstructured":"Kane J William HCJ Kujawa MJ Stringfellow J Marcus RN Sanchez R Meltzer HY Aripiprazole vs. perphenazine in treatment-resistant schizophrenia 156th Annual Meeting of the American Psychiatric Association; 2003 May 17-22; San Francisco, California, USA 2003"},{"issue":"2","key":"10.1002\/14651858.CD006617.pub3-BIB0037|cit37","doi-asserted-by":"crossref","first-page":"213","DOI":"10.4088\/JCP.v68n0206","article-title":"Aripiprazole for treatment-resistant schizophrenia : results of a multicenter, randomised, double-blind, comparison study versus perphenazine","volume":"68","author":"Kane","year":"2007","journal-title":"Journal of Clinical Psychiatry"},{"key":"10.1002\/14651858.CD006617.pub3-BIB0038|cit38","unstructured":"McQuade R Jody D Kane J Carson W Kujawa M Stringfellow J Marcus R Sanchez R Meltzer HY Efficacy and safety of aripiprazole versus perphenazine in treatment-resistant schizophrenia 16th European College of Neuropsychopharmacology Congress ; 2003 Sep 20-24; Prague, Czech Republic 2003"},{"issue":"4","key":"10.1002\/14651858.CD006617.pub3-BIB0039|cit39","doi-asserted-by":"crossref","first-page":"S326","DOI":"10.1016\/S0924-977X(03)92058-X","article-title":"Efficacy and safety of aripiprazole versus perphenazine in treatment-resistant schizophrenia","volume":"13","author":"McQuade","year":"2003","journal-title":"Journal of the European College of Neuropsychopharmacology"},{"key":"10.1002\/14651858.CD006617.pub3-BIB0040|cit40","unstructured":"Meltzer HY Kujawa MJ Carson Jr WH Stringfellow J Iwamoto T Marcus RN Stock EG Aripiprazole and perphenazine in severe treatment-resistant schizophrenia 157th Annual Meeting of the American Psychiatric Association; 2004 May 1-6; New York, Usa 2004"},{"issue":"Suppl.3","key":"10.1002\/14651858.CD006617.pub3-BIB0041|cit41","doi-asserted-by":"crossref","first-page":"S265","DOI":"10.1016\/S0924-977X(04)80296-7","article-title":"Efficacy of aripiprazole and perphenazine in svere schiziphrenia resistant to treatment with atypical antipsychotics","volume":"14","author":"Modell","year":"2004","journal-title":"Journal of the European College of Neuropsychopharmacology"},{"key":"10.1002\/14651858.CD006617.pub3-BIB0042|cit42","first-page":"502","article-title":"Aripiprazole versus Perphenazine in Treatment - Resistant Schizophrenia","volume":"31","author":"Sanchez","year":"2005","journal-title":"Schizophrenia Bulletin"},{"issue":"1","key":"10.1002\/14651858.CD006617.pub3-BIB0043|cit43","first-page":"155","article-title":"Effects of Long-Term Aripiprazole Therapy on the Negative Symptoms of Schizophrenia","volume":"67","author":"Archibald","year":"2004","journal-title":"Schizophrenia Research"},{"key":"10.1002\/14651858.CD006617.pub3-BIB0044|cit44","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/S0920-9964(03)80424-3","article-title":"Reduction in negative symptoms of schizophrenia during long-term therapy with aripiprazole","volume":"60","author":"Archibald","year":"2003","journal-title":"Schizophrenia Research"},{"key":"10.1002\/14651858.CD006617.pub3-BIB0045|cit45","unstructured":"Crandall D Pikalov A Kostic D Kaplita S Berman R McQuade R Radhakrishnan M Is sedation needed for effective reduction of acute schizophrenia symptoms ? 158th Annual Meeting of the American Psychiatric Association ; 2005 May 21-26; Atlanta, Georgia, USA 2005"},{"key":"10.1002\/14651858.CD006617.pub3-BIB0046|cit46","unstructured":"Dubitsky GM Harris R Laughren T Hardeman S Abilify (aripiprazole) tablets ; medical review part 3 www.fda.gov\/cder\/foi\/nda\/2002\/21-436_Abilify.htm 2002 111 75"},{"key":"10.1002\/14651858.CD006617.pub3-BIB0047|cit47","unstructured":"Dubitsky GM Harris R Laughren T Hardeman S Abilify (aripiprazole) tablets, medical review part 1 www.fda.gov\/cder\/foi\/nda\/2002\/21-436_Abilify.htm 2002 1 50"},{"key":"10.1002\/14651858.CD006617.pub3-BIB0048|cit48","unstructured":"Dubitsky GM Harris R Laughren T Hardeman S Abilify (aripiprazole) tablets ; medical review part 4 www.fda.gov\/cder\/foi\/nda\/2002\/21-436_Abilify.htm 2002 176 232"},{"key":"10.1002\/14651858.CD006617.pub3-BIB0049|cit49","unstructured":"Dubitsky GM Harris R Laughren T Hardeman s Abilify (aripiprazole) tablets ; medical review part 2 www.fda.gov\/cder\/foi\/nda\/2002\/21-436_Abilify.htm 2002 50 110"},{"key":"10.1002\/14651858.CD006617.pub3-BIB0050|cit50","unstructured":"European Medicines Agency Abilify H-C-471; European Public Assessment Report; Scientific discussion http:\/\/www.emea.europa.eu\/humandocs\/ 2007"},{"key":"10.1002\/14651858.CD006617.pub3-BIB0051|cit51","unstructured":"Kane JM Swyzen W Wu X McQuade R Gutierrez-Esteinou R Van Tran Q Marcus R Long-term symptomatic remission in schizophrenia patients treated with aripiprazole or haloperidol 159th Annual Meeting of the American Psychiatric Association ; 2006 May 20-25, Toronto, Canada 2006"},{"issue":"4","key":"10.1002\/14651858.CD006617.pub3-BIB0052|cit52","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1017\/S1461145703003651","article-title":"Efficacy and safety of aripiprazole vs. haloperidol for long-term maintenance treatment following acute relapse of schizophrenia","volume":"6","author":"Kasper","year":"2003","journal-title":"International Journal of Neuropsychopharmacology"},{"issue":"4","key":"10.1002\/14651858.CD006617.pub3-BIB0053|cit53","doi-asserted-by":"crossref","first-page":"S328","DOI":"10.1016\/S0924-977X(03)92064-5","article-title":"Long-term effects of aripiprazole on the negative symptoms of schizophrenia","volume":"13","author":"Kostic","year":"2003","journal-title":"Journal of the European College of Neuropsychopharmacology"},{"key":"10.1002\/14651858.CD006617.pub3-BIB0054|cit54","unstructured":"Kostic D Marcus RN Stock EG Carson WH Tourkodimitris S Archibald DG Maintenance of response in chronic schizophrenia : effects of aripiprazole and haloperidol on affective symptoms Schizophrenia Bulletin 2005 492"},{"key":"10.1002\/14651858.CD006617.pub3-BIB0055|cit55","first-page":"S186","article-title":"Aripiprazole for long-term maintenance treatment of schizophrenia","volume":"suppl 1","author":"Kujawa","year":"2002","journal-title":"International Journal of Neuropsychopharmacology"},{"key":"10.1002\/14651858.CD006617.pub3-BIB0056|cit56","unstructured":"Kujawa MJ Saha AR Ingenito GG Ali MW Luo X Archibald DG William Jr.HC Aripiprazole for long-term maintenance treatment in schizophrenia 155th Annual Meeting of the American Psychiatric Association; 2002 May 18-23; Philadelphia, PA, USA 2002"},{"key":"10.1002\/14651858.CD006617.pub3-BIB0057|cit57","unstructured":"Manos G Stock EG Jody D Archibald DG Tourkodimitris S Marcus RN Long-term effects of aripiprazole on the negative symptoms of schizophrenia 156th Annual Meeting of the American Psychiatric Association; 2003 May 17-22; San Francisco, USA 2003"},{"key":"10.1002\/14651858.CD006617.pub3-BIB0058|cit58","unstructured":"Marder SR Archibald DG Manos G Stock EG Jody DN Tourkodimitris S Marcus RN Iwamoto T Yamomoto Y Carson WH Long-term effects of aripiprazole therapy on the negative symptoms of schizophrenia XXIVth Collegium Internationale Neuro-Psychopharmacologicum Congress ; 2004 June 20-24 , Paris, France 2004"},{"issue":"Supplement 3","key":"10.1002\/14651858.CD006617.pub3-BIB0059|cit59","doi-asserted-by":"crossref","first-page":"S288","DOI":"10.1016\/S0924-977X(02)80405-9","article-title":"Aripiprazole for long-term maintenance treatment of schizophrenia","volume":"12","author":"McQuade","year":"2002","journal-title":"Journal of the European College of Neuropsychopharmacology"},{"key":"10.1002\/14651858.CD006617.pub3-BIB0060|cit60","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/S0920-9964(03)80498-X","article-title":"Aripiprazole for long-term maintenance treatment of schizophrenia","volume":"60","author":"McQuade","year":"2003","journal-title":"Schizophrenia Research"},{"issue":"Suppl.3","key":"10.1002\/14651858.CD006617.pub3-BIB0061|cit61","doi-asserted-by":"crossref","first-page":"S261","DOI":"10.1016\/S0924-977X(04)80287-6","article-title":"Long-term effects of aripiprazole on affective symptoms of schizophrenia","volume":"14","author":"Octavio","year":"2004","journal-title":"Journal of the European College of Neuropsychopharmacology"},{"key":"10.1002\/14651858.CD006617.pub3-BIB0062|cit62","unstructured":"Octavio I Stock EG Archibald DG Tourkodimitris S Kujawa MJ Marcus R Carson WH Iwamoto T Long-term effects of aripiprazole on affective symptoms of schizophrenia XXIVth Collegium Internationale Neuro-Psychopharmacologicum Congress ; 2004 June 20-24, Paris, France 2004"},{"key":"10.1002\/14651858.CD006617.pub3-BIB0063|cit63","unstructured":"Saha AR Carson WH Mcquade RD Stock EG Inada I Ali MW Long-term aripiprazole therapy in schizophrenia XIIth World Congress of Psychiatry; 2002 Aug 24-29; Yokohama, Japan 2002"},{"issue":"1","key":"10.1002\/14651858.CD006617.pub3-BIB0064|cit64","first-page":"158","article-title":"Long-Term Effects of Aripiprazole and Haloperidol on Affective Symptoms of Schizophrenia","volume":"67","author":"Stock","year":"2004","journal-title":"Schizophrenia Research"},{"key":"10.1002\/14651858.CD006617.pub3-BIB0065|cit65","unstructured":"Stock EG Achibald DG Tourkodimitris S Kuwaja MJ Marcus RN Carson Jr WH Long-term effects of aripiprazole on affective symptoms of schizophrenia 156th Annual Meeting of the American Psychiatric Association; 2003 May 17-22; San Francisco, USA 2003"},{"issue":"Nov","key":"10.1002\/14651858.CD006617.pub3-BIB0066|cit66","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1192\/bjp.bp.105.019307","article-title":"Comparative effectiveness of second-generation antipsychotics and haloperidol in acute schizophrenia","volume":"189","author":"McCue","year":"2006","journal-title":"British Journal of Psychiatry"},{"issue":"3","key":"10.1002\/14651858.CD006617.pub3-BIB0067|cit67","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1007\/s00213-006-0541-x","article-title":"Intramuscular aripiprazole for the treatment of acute agitation in patients with schizophrenia or schizoaffective disorder ; a double-blind, placebo-controlled comparison with intramuscular haloperidol","volume":"188","author":"Andrezina","year":"2006","journal-title":"Psychopharmacology"},{"key":"10.1002\/14651858.CD006617.pub3-BIB0068|cit68","unstructured":"Citrome LL Vester-Blokland E Archibald D McQuade R Kostic D Pikalov A Oren D Benefits of a second dose of intramuscular (im) aripiprazole to control agitation in patients with schizophrenia or bipolar 1 disorder 159th Annual Meeting of the American Psychiatric Association; 2006 May 20-25, Toronto, Canada 2006"},{"issue":"Suppl.3","key":"10.1002\/14651858.CD006617.pub3-BIB0069|cit69","first-page":"S509","article-title":"Comparison of intramuscular aripiprazole and haloperidol with placebo in acutely agitated schizophrenia patients","volume":"15","author":"Dillenschneider","year":"2005","journal-title":"Journal of the European College of Neuropsychopharmacology"},{"key":"10.1002\/14651858.CD006617.pub3-BIB0070|cit70","unstructured":"McQuade R Auby P Oren D Marcus R Kostic D Iwamoto T Manos G Intramuscular aripiprazole in acute schizophrenia : a double-blind, placebo-controlled comparison with IM haloperidol 13th Biennial winter workshop on Schizophrenia Research; 2006 February 4-10, Davos, Switzerland 2006"},{"key":"10.1002\/14651858.CD006617.pub3-BIB0071|cit71","first-page":"399","article-title":"Efficacy and Safety of Intramuscular Aripiprazole, Haloperidol or Placebo in Acutely Agitated Patients with Schizophrenia or Schizoaffective Disorder","volume":"31","author":"Oren","year":"2005","journal-title":"Schizophrenia Bulletin"},{"key":"10.1002\/14651858.CD006617.pub3-BIB0072|cit72","unstructured":"Oren D Marcus R Kostic D McQuade R Iwamoto T Archibald D Efficacy and safety of intramuscular aripiprazole, haloperidol or placebo in acutely agitated patients with schizophrenia or schizoaffective disorder 158th Annual Meeting of the American Psychiatric Association; 2005 May 21-26, Atlanta, GA, USA 2005"},{"key":"10.1002\/14651858.CD006617.pub3-BIB0073|cit73","unstructured":"Yocca F Marcus R Oren D Manos G Carson W Iwamoto T Stock E Intramuscular aripiprazole in acute schizophrenia: A pivotal phase-three study 158th Annual Meeting of the American Psychiatric Association; 2005 May 21-26; Atlanta, GA, USA 2005"},{"issue":"4","key":"10.1002\/14651858.CD006617.pub3-BIB0074|cit74","first-page":"250","article-title":"A comparative study between aripiprazole and chlorpromazine in the treatment of schizophrenia","volume":"18","author":"Wang","year":"2005","journal-title":"Shandong Archives of Psychiatry"},{"issue":"2","key":"10.1002\/14651858.CD006617.pub3-BIB0075|cit75","first-page":"418","article-title":"Similar rates of agitation, anxiety and insomnia in sedating and non-sedating antipsychotics: evaluating clinical trial results with aripiprazole, haloperidol and olanzapine","volume":"33","author":"Allen","year":"2007","journal-title":"Schizophrenia Bulletin"},{"issue":"11","key":"10.1002\/14651858.CD006617.pub3-BIB0076|cit76","doi-asserted-by":"crossref","first-page":"2209","DOI":"10.1185\/030079906X148445","article-title":"Intramuscular aripiprazole or haloperidol and transition to oral therapy in patients with agitation associated with schizophrenia: sub-analysis of a double-blind study","volume":"22","author":"Andrezina","year":"2006","journal-title":"Current Medical Research and Opinion"},{"issue":"2","key":"10.1002\/14651858.CD006617.pub3-BIB0077|cit77","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1592\/phco.24.2.212.33145","article-title":"Aripiprazole, a novel atypical antipsychotic drug","volume":"24","author":"Argo","year":"2004","journal-title":"Pharmacotherapy"},{"key":"10.1002\/14651858.CD006617.pub3-BIB0078|cit78","unstructured":"Carson WH Ingenito GG McQuade RD Stock EG Iwamoto T XIIth World Congress of Psychiatry; Aug 24-29; Yokohama, Japan 2002"},{"key":"10.1002\/14651858.CD006617.pub3-BIB0079|cit79","unstructured":"Carson W Marcus R Jody D Liston H Pans M Riera L Iwamoto T The effectiveness of switch to aripiprazole stratified by prior antipsychotic American Psychiatric Association Annual Meeting; 2004 May 1-6, New York, NY, USA 2004"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD006617.pub3-BIB0080|cit80","first-page":"S187","article-title":"Switching to aripiprazole monotherapy","volume":"5","author":"Casey","year":"2002","journal-title":"International Journal of Neuropsychopharmacology"},{"issue":"4","key":"10.1002\/14651858.CD006617.pub3-BIB0081|cit81","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1007\/s00213-002-1344-3","article-title":"Switching patients to aripiprazole from other antipsychotic agents : a multicenter randomised study","volume":"166","author":"Casey","year":"2003","journal-title":"Psychopharmacology"},{"key":"10.1002\/14651858.CD006617.pub3-BIB0082|cit82","unstructured":"Casey DE Saha AR Ali MW Jody D Kujawa MJ Stock EG Ingenito GG Switching to aripiprazole monotherapy 155th Annual Meeting of the American Psychiatric Association; 2002 May 18-23; Philadelphia, Pennysylvania, USA 2002"},{"key":"10.1002\/14651858.CD006617.pub3-BIB0083|cit83","unstructured":"Dubitsky GM Harris R Laughren T Hardeman S Abilify (aripiprazole) tablets ; medical review part 1 www.fda.gov\/cder\/foi\/nda\/2002\/21-436_Abilify.htm 2002 1 50"},{"key":"10.1002\/14651858.CD006617.pub3-BIB0084|cit84","unstructured":"Dubitsky GM Harris R Laughren T Hardeman S Abilify (aripiprazole) tablets ; medical review part 2 www.fda.gov\/cder\/foi\/nda\/2002\/21-436_Abilify.htm 2002 50 110"},{"key":"10.1002\/14651858.CD006617.pub3-BIB0085|cit85","unstructured":"Dubitsky GM Harris R Laughren T Hardeman S Abilify (aripiprazole) tablets ; medical review part 3 www.fda.gov\/cder\/foi\/nda\/2002\/21-436_Abilify.htm 2002 111 75"},{"key":"10.1002\/14651858.CD006617.pub3-BIB0086|cit86","unstructured":"Dubitsky GM Harris R Laughren T Hardeman S Abilify (aripiprazole) tablets ; medical review part 4 www.fda.gov\/cder\/foi\/nda\/2002\/21-436_Abilify.htm 2002 176 232"},{"key":"10.1002\/14651858.CD006617.pub3-BIB0087|cit87","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1016\/S0920-9964(03)80483-8","article-title":"Switching to aripiprazole monotherapy","volume":"60","author":"Kujawa","year":"2003","journal-title":"Schizophrenia Research"},{"issue":"Suppl 3","key":"10.1002\/14651858.CD006617.pub3-BIB0088|cit88","doi-asserted-by":"crossref","first-page":"S292","DOI":"10.1016\/S0924-977X(02)80418-7","article-title":"Switching to aripiprazole monotherapy","volume":"12","author":"Medori","year":"2002","journal-title":"Journal of the European College of Neuropsychopharmacology"},{"issue":"2","key":"10.1002\/14651858.CD006617.pub3-BIB0089|cit89","first-page":"434","article-title":"Drug interactions between aripiprazole and haloperidol: double blind, placebo controlled study","volume":"33","author":"Jung","year":"2007","journal-title":"Schizophrenia Bulletin"},{"issue":"Suppl 4","key":"10.1002\/14651858.CD006617.pub3-BIB0090|cit90","doi-asserted-by":"crossref","first-page":"S430","DOI":"10.1016\/S0924-977X(06)70549-1","article-title":"Do second-generation antipsychotics disrupt decision-making abilities in schizophrenia ?","volume":"16","author":"Kelemen","year":"2006","journal-title":"Journal of the European College of Neuropsychopharmacology"},{"issue":"Suppl 4","key":"10.1002\/14651858.CD006617.pub3-BIB0091|cit91","doi-asserted-by":"crossref","first-page":"S417","DOI":"10.1016\/S0924-977X(06)70527-2","article-title":"The comparison of efficacy between aripiprazole and haloperidol in treatment of chronic schizophrenia and schizoaffective disorder : results for 16-week clinical study","volume":"16","author":"Kim","year":"2006","journal-title":"Journal of the European College of Neuropsychopharmacology"},{"issue":"2","key":"10.1002\/14651858.CD006617.pub3-BIB0092|cit92","first-page":"437","article-title":"Efficacy and safety of aripiprazole a 12 weeks, multi-center, open-label switching to aripiprazole study in stable outpatients with schizophrenia or schizoaffective disorder","volume":"33","author":"Kim","year":"2007","journal-title":"Schizophrenia Bulletin"},{"key":"10.1002\/14651858.CD006617.pub3-BIB0093|cit93","doi-asserted-by":"crossref","unstructured":"Petrie JL Saha JR McEvoy JP Aripiprazole, a new typical antipsychotic: phase 2 clinical trial result 10th European College of Neuropsychopharmacology Congres; Sep 13-17; Vienna, Austria. 1997","DOI":"10.1016\/S0924-977X(97)88746-9"},{"issue":"Suppl 4","key":"10.1002\/14651858.CD006617.pub3-BIB0094|cit94","doi-asserted-by":"crossref","first-page":"S405","DOI":"10.1016\/S0924-977X(06)70504-1","article-title":"Adjunctive treatment with a dopamine partial agonist, aripiprazole for antipsychotic-induced hyperprolactinaemia","volume":"16","author":"Shim","year":"2006","journal-title":"Journal of the European College of Neuropsychopharmacology"},{"key":"10.1002\/14651858.CD006617.pub3-BIB0095|cit95","unstructured":"Swanson JW Swartz MS Van Dorn RA Effectiveness of atypical antipsychotics for substance abuse in schizophrenia patients 159th Annual Meeting of the American Psychiatric Association; 2006 May 20-25, Toronto, Canada. 2006"},{"key":"10.1002\/14651858.CD006617.pub3-BIB0096|cit96","unstructured":"Talbott S Buckley P Eudicone J McQuade R Van-Tran Q Akathisia in schizophrenia patients treated with aripiprazole, haloperidol, or olanzapine-analyses of the first 12 weeks of three double-blind, long-term trials 11th International Congress on Schizophrenia Research; 2007 Mar 28-Apr 1, Colorado Springs, Colorado, USA 2007"},{"issue":"1","key":"10.1002\/14651858.CD006617.pub3-BIB0097|cit97","first-page":"64","article-title":"Effect of aripiprazole or haldol on intelligence and memory in the first-onset schizophrenia","volume":"12","author":"Wu","year":"2006","journal-title":"Chinese Journal of Rehabilitation Theory and Practice"},{"issue":"10","key":"10.1002\/14651858.CD006617.pub3-BIB0098|cit98","first-page":"33","article-title":"A treatment study of schizophrenia with aripiprazole and chlorpromazine","volume":"6","author":"Xia","year":"2005","journal-title":"Practical Clinical Medicine"},{"issue":"17","key":"10.1002\/14651858.CD006617.pub3-BIB0099|cit99","first-page":"719","article-title":"Comparative study between aripiprazole and chlorpromazine in the treatment of female patients with schizophrenia","volume":"18","author":"Ao","year":"2006","journal-title":"Title only available in chinese characters"},{"issue":"3","key":"10.1002\/14651858.CD006617.pub3-BIB0100|cit100","first-page":"203","article-title":"Title only available in Chinese characters","volume":"6","author":"Cheng","year":"2006","journal-title":"Nervous Diseases and Mental Health"},{"key":"10.1002\/14651858.CD006617.pub3-BIB0101|cit101","unstructured":"Currier GW Crandall D Archibald D Nyilas M Kostic D Pikalov A Oren D Intramuscular (im) aripiprazole controls agitation in patients with schizophrenia or bipolar disorder without excessive sedation 159th Annual Meeting of the American Psychiatric Association; 2006 May 20-25, Toronto, Canada 2006"},{"key":"10.1002\/14651858.CD006617.pub3-BIB0102|cit102","unstructured":"Daniel DG Crandall D Manos G McQuade RD Gutierrez-Esteinou R Pikalov AA Oren D Transitioning from intramuscular (im) to oral aripiprazole in patients with schizophrenia 159th Annual Meeting of the American Psychiatric Association; 2006 May 20-25, Toronto, Canada 2006"},{"issue":"2","key":"10.1002\/14651858.CD006617.pub3-BIB0103|cit103","first-page":"426","article-title":"Transitioning from intramuscular (IM) to oral aripiprazole in patients with schizophrenia TTransitioning from intramuscular (IM) to oral aripiprazole in patients with schizophrenia","volume":"33","author":"Daniel","year":"2007","journal-title":"Schizophrenia Bulletin"},{"issue":"5","key":"10.1002\/14651858.CD006617.pub3-BIB0104|cit104","first-page":"440","article-title":"Effects of aripiprazole and chlorpromazine on the cognitive function in first-episode schizophrenia patients","volume":"15","author":"Lin","year":"2006","journal-title":"Title in Chinese characters"},{"issue":"2","key":"10.1002\/14651858.CD006617.pub3-BIB0105|cit105","first-page":"90","article-title":"A comparative study of aripiprazole and chlorpromazine in the treatment of schizophrenia","volume":"19","author":"Lu","year":"2006","journal-title":"Title in Chinese characters"},{"issue":"1","key":"10.1002\/14651858.CD006617.pub3-BIB0106|cit106","first-page":"38","article-title":"A comparative study of aripiprazole and haloperidol in the treatment of patient with treatment-resistant schizophrenia","volume":"6","author":"Wang","year":"2006","journal-title":"Title in Chinese characters"},{"issue":"9","key":"10.1002\/14651858.CD006617.pub3-BIB0107|cit107","first-page":"737","article-title":"The clinic study of the change medicine ways about aripiprazole","volume":"18","author":"Xu","year":"2006","journal-title":"Medical Journal of Chinese Peoples Health"},{"issue":"5","key":"10.1002\/14651858.CD006617.pub3-BIB0108|cit108","first-page":"374","article-title":"Title only available in Chinese characters","volume":"5","author":"Zhang","year":"2005","journal-title":"Nervous Diseases and Mental Health"},{"issue":"1","key":"10.1002\/14651858.CD006617.pub3-BIB0109|cit109","first-page":"11","article-title":"Title only available in Chinese characters","volume":"18","author":"Zhang","year":"2006","journal-title":"Medical Journal of Chinese Peoples Health"},{"issue":"2","key":"10.1002\/14651858.CD006617.pub3-BIB0110|cit110","first-page":"111","article-title":"Title only available in Chinese characters","volume":"16","author":"Zhuang","year":"2006","journal-title":"Only available in Chinese characters"},{"key":"10.1002\/14651858.CD006617.pub3-BIB0111|cit111","unstructured":"Barbui C Tansella M Randomized evaluation of the effectiveness of clozapine and aripiprazole versus clozapine and haloperidol in the treatment of schizophrenia. An independent, pragmatic, multicentre, parallel-group, superiority trial http:\/\/www.clinicaltrials.gov 2006"},{"key":"10.1002\/14651858.CD006617.pub3-BIB0112|cit112","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1136\/bmj.313.7066.1200","article-title":"Detecting skewness from summary information","volume":"313","author":"Altman","year":"1996","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD006617.pub3-BIB0113|cit113","first-page":"1","article-title":"Negative syndrome in schizophrenia: strategies for long-term management","volume":"40","author":"Andreasen","year":"1985","journal-title":"Advances in Biochemical Psychopharmacology"},{"key":"10.1002\/14651858.CD006617.pub3-BIB0114|cit114","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1136\/bmj.315.7108.600","article-title":"Statistics notes. Trials randomised in clusters","volume":"315","author":"Bland","year":"1997","journal-title":"BMJ"},{"issue":"4","key":"10.1002\/14651858.CD006617.pub3-BIB0115|cit115","first-page":"405","article-title":"The problem of therapeutic efficacy indices. 3. Comparison of the indices and their use","volume":"54","author":"Boissel","year":"1999","journal-title":"Therapie"},{"key":"10.1002\/14651858.CD006617.pub3-BIB0116|cit116","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1093\/schbul\/10.3.388","article-title":"The quality of life scale: an instrument for rating the schizophrenic deficit syndrome.","volume":"10","author":"Heinrichs","year":"1984","journal-title":"Schizophrenia Bulletin"},{"key":"10.1002\/14651858.CD006617.pub3-BIB0117|cit117","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1056\/NEJM199403103301006","article-title":"Schizophrenia","volume":"330","author":"Carpenter","year":"1994","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD006617.pub3-BIB0118|cit118","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1093\/schbul\/17.2.217","article-title":"When symptoms persist: choosing among alternative somatic symptoms for schizophrenia","volume":"17","author":"Christison","year":"1991","journal-title":"Schizophrenia Bulletin"},{"key":"10.1002\/14651858.CD006617.pub3-BIB0119|cit119","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1192\/S0007125000071919","article-title":"Positive and negative schizophrenic symptoms and the role of dopamine","volume":"137","author":"Crow","year":"1980","journal-title":"British Journal of Psychiatry"},{"key":"10.1002\/14651858.CD006617.pub3-BIB0120|cit120","doi-asserted-by":"crossref","first-page":"260","DOI":"10.2165\/00003495-197714040-00002","article-title":"Antipsychotic drugs: clinical pharmacology and therapeutic use","volume":"14","author":"Davis","year":"1977","journal-title":"Drugs"},{"key":"10.1002\/14651858.CD006617.pub3-BIB0121|cit121","unstructured":"Deeks J Issues in the selection for meta-analysis of binary data In: Abstracts of 8th InternationalCochrane Colloquim; 2000 Oct 25-28th; Cape Town, South Africa 2000"},{"key":"10.1002\/14651858.CD006617.pub3-BIB0122|cit122","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1007\/BF02599201","article-title":"The unit of analysis error in studies about physicians' patient care behaviour","volume":"7","author":"Divine","year":"1992","journal-title":"Journal of General Internal Medicine"},{"key":"10.1002\/14651858.CD006617.pub3-BIB0123|cit123","doi-asserted-by":"crossref","first-page":"2971","DOI":"10.1002\/sim.1301","article-title":"Issues in the meta-analysis of cluster randomised trials","volume":"21","author":"Donner","year":"2002","journal-title":"Statistics in Medicine"},{"issue":"2","key":"10.1002\/14651858.CD006617.pub3-BIB0124|cit124","article-title":"Aripiprazole for schizophrenia","author":"El-Sayeh","year":"2006","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD006617.pub3-BIB0125|cit125","unstructured":"U.S. Federal Drug Administration CDER Abilify (aripiprazole) tablets, medical review www.fda.gov\/cder\/foi\/nda\/2002\/21-436_Abilify.htm 2002"},{"key":"10.1002\/14651858.CD006617.pub3-BIB0126|cit126","first-page":"1314","article-title":"Antipsychotic and anticholinergic drugs","volume-title":"New Oxford Textbook of Psychiatry","volume":"2","author":"Gelder","year":"2000"},{"key":"10.1002\/14651858.CD006617.pub3-BIB0127|cit127","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1093\/oxfordjournals.aje.a009904","article-title":"Components of variance and intraclass correlations for the design of community-based surveys and intervention studies: data from the Health Survey for England 1994","volume":"149","author":"Gulliford","year":"1999","journal-title":"American Journal of Epidemiology"},{"key":"10.1002\/14651858.CD006617.pub3-BIB0128|cit128","volume-title":"ECDEU assessment manual for psychopharmacology","author":"Guy","year":"1976"},{"key":"10.1002\/14651858.CD006617.pub3-BIB0129|cit129","first-page":"48","article-title":"The Brief Psychiatric Rating Scale (BPRS): a comprehensive review","volume":"11","author":"Hedlund","year":"1980","journal-title":"Journal of Operational Psychiatry"},{"key":"10.1002\/14651858.CD006617.pub3-BIB0130|cit130","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analysis","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD006617.pub3-BIB0131|cit131","unstructured":"Higgins JPT Green S editor(s) Cochrane Handbook for Systematic Reviews of Interventions 4.2.5 [updated May 2005] The Cochrane Library 2005"},{"key":"10.1002\/14651858.CD006617.pub3-BIB0132|cit132","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0197-2456(95)00134-4","article-title":"Assessing the quality of reports of randomized clinical trials: is blinding necessary?","volume":"17","author":"Jadad","year":"1996","journal-title":"Controlled clinical trials"},{"issue":"1","key":"10.1002\/14651858.CD006617.pub3-BIB0133|cit133","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD003082.pub2","article-title":"Haloperidol versus placebo for schizophrenia","author":"Joy","year":"2004","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD006617.pub3-BIB0134|cit134","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1136\/bmj.323.7303.42","article-title":"Systematic reviews in health care: Assessing the quality of controlled clinical trials","volume":"323","author":"J\u00fcni","year":"2001","journal-title":"BMJ"},{"issue":"suppl","key":"10.1002\/14651858.CD006617.pub3-BIB0135|cit135","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1111\/j.1600-0447.1990.tb05309.x","article-title":"Treatment programme and long term outcome in chronic schizophrenia","volume":"358","author":"Kane","year":"1990","journal-title":"Acta Psychiatrica Scandinavica"},{"key":"10.1002\/14651858.CD006617.pub3-BIB0136|cit136","first-page":"585","article-title":"Treatment programme and long term outcome in chronic schizophrenia","volume":"46","author":"Kane","year":"1993","journal-title":"Acta Psychiatrica Scandinavica"},{"key":"10.1002\/14651858.CD006617.pub3-BIB0137|cit137","volume-title":"Positive and negative syndrome scale (PANSS) manual","author":"Kay","year":"1986"},{"key":"10.1002\/14651858.CD006617.pub3-BIB0138|cit138","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1192\/bjp.187.4.366","article-title":"Clinical implications of Brief Psychiatric Rating Scale Scores","volume":"187","author":"Leucht","year":"2005","journal-title":"British Journal of Psychiatry"},{"key":"10.1002\/14651858.CD006617.pub3-BIB0139|cit139","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.schres.2005.04.008","article-title":"What does the PANSS mean?","volume":"79","author":"Leucht","year":"2005","journal-title":"Schizophrenia Research"},{"key":"10.1002\/14651858.CD006617.pub3-BIB0140|cit140","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/S0920-9964(03)00087-2","article-title":"An excitement subscale of the Positive and Negative Syndrome Scale","volume":"68","author":"Lindenmeyer","year":"2004","journal-title":"Schizophrenia research"},{"key":"10.1002\/14651858.CD006617.pub3-BIB0141|cit141","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1192\/bjp.176.3.249","article-title":"Unpublished rating scales - a major source of bias in randomised controlled trials of treatments for schizophrenia?","volume":"176","author":"Marshall","year":"2000","journal-title":"British Journal of Psychiatry"},{"key":"10.1002\/14651858.CD006617.pub3-BIB0142|cit142","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1093\/schbul\/18.3.515","article-title":"Treatment of the neuroleptic-nonresponsive schizophrenic patient","volume":"18","author":"Meltzer","year":"1992","journal-title":"Schizophrenia Bulletin"},{"key":"10.1002\/14651858.CD006617.pub3-BIB0143|cit143","doi-asserted-by":"crossref","first-page":"1987","DOI":"10.1001\/jama.285.15.1987","article-title":"The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomized trials","volume":"285","author":"Moher","year":"2001","journal-title":"JAMA"},{"key":"10.1002\/14651858.CD006617.pub3-BIB0144|cit144","doi-asserted-by":"crossref","first-page":"799","DOI":"10.2466\/pr0.1962.10.3.799","article-title":"The Brief Psychiatric Rating Scale","volume":"10","author":"Overall","year":"1962","journal-title":"Psychological Reports"},{"issue":"1","key":"10.1002\/14651858.CD006617.pub3-BIB0145|cit145","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1037\/0735-7028.34.1.108","article-title":"Aripiprazole: A novel antipsychotic with dopamine stabilising properties","volume":"34","author":"Rivas-Vasquez","year":"2003","journal-title":"Professional Psychology: Research and Practice"},{"issue":"7127","key":"10.1002\/14651858.CD006617.pub3-BIB0146|cit146","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1136\/bmj.316.7127.285","article-title":"What are pragmatic trials?","volume":"316","author":"Roland","year":"1998","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD006617.pub3-BIB0147|cit147","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1001\/jama.1995.03520290060030","article-title":"Empirical evidence of bias: dimensions of methodological quality associated with estimates of treatment effects in controlled trials","volume":"273","author":"Schulz","year":"1995","journal-title":"JAMA"},{"issue":"5","key":"10.1002\/14651858.CD006617.pub3-BIB0148|cit148","doi-asserted-by":"crossref","first-page":"3","DOI":"10.3310\/hta3050","article-title":"Methods for evaluating area-wide and organisation-based interventions in health and health care: a systematic review","volume":"3","author":"Ukoumunne","year":"1999","journal-title":"Health Technology Assessment"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1002\/14651858.CD006617.pub3\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,18]],"date-time":"2023-10-18T05:09:50Z","timestamp":1697605790000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/14651858.CD006617.pub3"}},"subtitle":[],"editor":[{"name":"Cochrane Schizophrenia Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2008,7,16]]},"references-count":148,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2014,7]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd006617.pub3","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,7,16]]}}}